Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Stellari (Parma, Pr, Italy). Pharmacological validation of a new IPF bleomycin-induced mouse model. 1053

Member's Comments

No comment yet.

Related content which might interest you: A longitudinal characterization of lymphangiogenesis in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation Year: 2012 Effect of Nintedanib in a rat model of bleomycin-induced lung fibrosis: a transcriptome analysis Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021 The novel oligonucleotide therapeutics PK-7010 for TGF-ß1 ameliorates bleomycin-induced pulmonary fibrosis in mice Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Late Breaking Abstract - MIF inhibition in a murine model of bleomycin-induced lung fibrosis Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation versus fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 396s Year: 2006 Time-course analysis of bleomycin-induced lung fibrosis in the rat Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Development of an integrative approach to identify key molecular targets involved in bleomycin-induced pulmonary fibrosis in rats. Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 A humanized animal model of pulmonary fibrosis based on cellular senescence Source: Virtual Congress 2020 – Cellular involvement in lung injury Year: 2020 Quantitation of hydroxyproline in a mouse model of bleomycin-induced lung fibrosis: comparison with histological analysis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 The effect of pravastatin on bleomycin-induced lung injury and fibrosis in mouse Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Progress in modelling acute lung injury in a pre-clinical mouse model Source: Eur Respir J 2012; 39: 1062-1063 Year: 2012 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Late Breaking Abstract - PRRX1 inhibition decreases fibrosis in the bleomycin-induced lung fibrosis model in mice Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018